Benzinga's Volume Movers

shares climbed 30.70 percent to $57.42. The volume of Spark Therapeutics shares traded was 2008 percent higher than normal. Spark Therapeutics reported positive top-line results from the pivotal Phase 3 trial of SPK-RPE65 for genetic blinding conditions.

surged 2.34 percent to $45.52. The volume of Dow Chemical shares traded was 1221 percent higher than normal. Dow reported preliminary results of its exchange offer for chlorine value chain business.

shares moved up 7.04 percent to $15.50. The volume of MakeMyTrip traded was 292 percent higher than normal. MakeMyTrip shares have dipped 45.93 percent over the past 52 weeks, while the S&P 500 index has declined 0.84 percent in the same period.

shares rose 13.65 percent to $31.88. The volume of Acorda Therapeutics shares traded was 271 percent higher than normal. Acorda Therapeutics agreed with Actavis to resolve pending patent litigation brought by Acorda against Actavis involving Ampyra Extended-Release Tablets.